Olmevas AM: A Combined Antihypertensive for Blood Pressure Control

Olmevas AM is a combined antihypertensive preparation containing Amlodipine and Olmesartan Medoxomil. It is indicated for the treatment of hypertension, either alone or with other antihypertensive agents, to lower blood pressure. It can also be used as initial therapy in patients likely to need multiple agents to reach their blood pressure goals, with individualized decisions based on baseline blood pressure, target goal, and likelihood of achieving goal with combination therapy.

How Olmevas AM Works (Pharmacology)

Olmevas AM combines two distinct mechanisms to lower blood pressure:

1. Amlodipine (Dihydropyridine Calcium Channel Blocker):
   • Inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.
   • Has a greater effect on vascular smooth muscle, causing peripheral arterial vasodilation.
   • This directly reduces peripheral vascular resistance, leading to a reduction in blood pressure.
2. Olmesartan Medoxomil (Angiotensin II Receptor Blocker - ARB):
   • Angiotensin II is a potent vasoconstrictor and a primary vasoactive hormone of the Renin-Angiotensin System (RAS), playing a crucial role in hypertension. It also stimulates aldosterone secretion.
   • Olmesartan Medoxomil selectively blocks the binding of angiotensin II to the AT1 receptor (found in vascular smooth muscle, adrenal gland, etc.).
   • By blocking these receptors, it inhibits the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
   • It does not inhibit ACE (angiotensin-converting enzyme), which is involved in converting angiotensin I to angiotensin II and degrading bradykinin.

Key Indications & Benefits

Olmevas AM is indicated for:

• Treatment of hypertension, alone or with other antihypertensive agents.
• Initial therapy in patients likely to require multiple antihypertensive agents to achieve blood pressure goals.

Dosage & Administration

Always consult a registered physician for medication use.

• Substitute for individually titrated components: For patients already on Amlodipine and Olmesartan Medoxomil, this combination can substitute the individual components.
• Dosage Adjustment: This combination may also be given with increased amounts of Amlodipine, Olmesartan Medoxomil, or both, as needed.
• Initial therapy: Initiate with 5/20 mg once daily for 1 to 2 weeks and titrate as needed up to a maximum of 10/40 mg once daily.
• Elderly patients (75 years and older): Due to decreased clearance of Amlodipine, the recommended starting dose of Amlodipine is 2.5 mg. Since the lowest dose of this combination is 5/20 mg, initial therapy with Olmevas AM is not recommended in patients >75 years old.

Important Considerations & Warnings

It is crucial to discuss your full medical history with your doctor before taking Olmevas AM.

Contraindications:

• Cannot be co-administered with Aliskiren in patients with diabetes.

Side Effects:

• Most common: Peripheral edema (swelling, usually in ankles), headache, flushing, and dizziness.
• Can also cause intestinal problems known as sprue-like enteropathy (severe, chronic diarrhea with substantial weight loss).

Pregnancy & Lactation:

• Pregnancy Category D.
• Should not be used in the 2nd and 3rd trimesters of pregnancy because it can cause fetal death.
• When pregnancy is detected, this combination should be discontinued as soon as possible.
• Lactation: It is not known whether Olmesartan and Amlodipine are excreted in human milk. Due to the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, considering its importance to the mother.

Precautions & Warnings:

Olmevas AM should be used with caution due to the risk of:

• Hypotension in volume- or salt-depleted patients.
• Vasodilation in patients with severe aortic stenosis.
• Increased frequency, duration, or severity of angina or acute myocardial infarction (MI) in patients with severe obstructive coronary artery disease.

Drug Interactions:

• NSAIDs (including selective COX-2 inhibitors): The antihypertensive effect of angiotensin II receptor antagonists, including Olmesartan Medoxomil, may be attenuated (reduced) by NSAIDs.
• Other agents affecting the RAS: Blood pressure, renal function, and electrolytes should be closely monitored in patients on combination therapy with other agents that affect the Renin-Angiotensin System.

Use in Special Populations:

• Pediatric use: Safety and effectiveness have not been established in pediatric patients.
• Geriatric use: No overall differences in safety or effectiveness were observed between subjects 65 years of age or older and younger subjects. (Note: Initial therapy is not recommended for those >75 years due to amlodipine component).
• Renal impairment: There are no specific studies in patients with renal impairment with this combination.
• Hepatic impairment: Initial therapy is not recommended in hepatically impaired patients.

Overdose Effects

• There is no information on overdosage in humans for this specific combination.
• In case of overdose, general supportive measures should be employed.

Storage Conditions

Do not store above 30°C. Keep away from light and out of the reach of children.